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AbstrAct
Introduction Pneumothorax is a common clinical 
problem. Primary spontaneous pneumothorax (PSP) occurs 
in otherwise fit young patients, but optimal management 
is not clearly defined and often results in a long hospital 
stay. Ambulatory treatment options are available, but the 
existing data on their efficacy are poor. The Randomised 
Ambulatory Management of Primary Pneumothorax trial 
is a multicentre, randomised controlled trial comparing 
ambulatory management with standard care, specifically 
designed to safely and effectively reduce hospital stay.
Methods and analysis 236 patients with PSP will be 
recruited from UK hospitals. Patients will be randomised 
1:1 to treatment to either the ‘Intervention’ arm 
(ambulatory device; Rocket Pleural Vent) or the ‘Control’ 
arm (aspiration ± standard chest drain insertion). Patients 
will be followed up for a total of 12 months to assess 
recurrence rates. The primary outcome is total length of 
stay in hospital (including readmissions) up to 30 days 
postrandomisation. The secondary outcomes are pain 
and breathlessness scores, air leak measurement and 
radiological evidence (on CT scanning) of emphysema-
like changes, compared with short-term and long-term 
outcomes, respectively, and health economic analysis.
Ethics and dissemination The trial has received ethical 
approval from the National Research Ethics Service 
Committee South-Central Oxford A (15/SC/0240).
trial registration number ISRCTN79151659
IntroductIon
Pneumothorax—air in the pleural space—is 
a common pathology. Primary spontaneous 
pneumothorax (PSP) conventionally refers 
to patients developing a pneumothorax, 
in the absence of trauma, with no under-
lying established lung pathology. PSP occurs 
in ~3000 patients per year in the UK.1–3 A 
minority can be managed conservatively with 
close observation only. A currently recruiting 
trial is assessing conservative versus interven-
tional management.4 However, many patients 
will require an intervention to re-expand 
the lung. In most patients ‘aspiration’ of the 
trapped air using a cannula and syringe is 
considered, but more than 50% will require 
treatment with insertion of a chest drain and 
a standard underwater seal. The average dura-
tion of inpatient stay of patients admitted for 
drainage is 6–8 days.5
Ambulatory management of patients with 
PSP could potentially remove the need for 
long hospital admission and outpatient treat-
ment. Reducing the need for chest drains 
with bulky underwater systems may allow 
patients to be more mobile and facilitate 
earlier discharge. A ‘Heimlich valve’ (one-way 
valve connected to a chest drain, rather than 
a bulky underwater seal) has been previously 
proposed, in the form of either one-way valves 
attached to standard chest drains, as well as 
the relatively new ‘pocket’ devices in which 
the drainage catheter and one-way valve are 
integrated into a single device. A system-
atic review of 18 studies using ambulatory 
management reported an overall success rate 
of 85.8% and a successful outpatient manage-
ment in 77.9% with ‘few complications’. 
However, the evidence was of poor quality 
with a high risk of bias, with only two small 
randomised trials and with the remainder 
being retrospective case series.6
The Randomised Ambulatory Manage-
ment of Primary Pneumothorax (RAMPP) 
trial aims to provide randomised controlled 
trial data to definitively answer the question 
of whether an ambulatory management of 
patients with PSP can safely and effectively 
reduce hospital stay. The ambulatory device 
used in this trial is Rocket Pleural Vent 
(Rocket Medical, UK), specifically designed 
for treatment of pneumothorax.
At present, there exist no good predictive 
data to guide management of either short-
term failure of initial management (with 
ongoing air leak or non-re-expanding lung) 
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or long-term with recurrence of pneumothorax. There-
fore, the RAMPP trial will also prospectively collect 
clinical data, including daily air leak measurement and 
Computed Tomography (CT) imaging on all patients to 
potentially generate a predictive tool allowing the selec-
tive and targeted treatment of patients according to likely 
outcome, resulting in more personalised treatment (and 
intended to be published separately from the main find-
ings of the study).
This study, evaluating the randomised ambulatory 
management of primary pneumothorax (RAMPP trial), 
is a multicentre, open-label, randomised controlled trial 
comparing ambulatory management with standard care 
(aspiration ± standard chest drain insertion) with an 
observational cohort study of patients not requiring an 
intervention. The trial is sponsored by the University of 
Oxford and is being managed by the Oxford Respiratory 
Trials Unit (ORTU). Data management is undertaken by 
ORTU.
The trial is registered on the International Stan-
dardised Randomised Controlled Trial Registry. The 
study is included in the National Institute for Health 
Research Clinical Research Network portfolio for both 
respiratory and emergency medicine.
The following is the primary research question: for 
patients with PSP, can use of an ambulatory device and 
treatment strategy significantly reduce hospital stay 
within the first 30 days of initial presentation?
The following are the secondary research questions:
 ► Is ambulatory care and early discharge safe and 
cost-effective?
 ► Is patient experience improved with an ambulatory 
device, including pain of procedure, breathlessness, 
quality of life assessments (EuroQol EQ-5D-5L) and 
time to return to working status?
 ► What is the recurrence rate of pneumothorax over 6 
and 12 months?
 ► Does radiological evidence (on CT scanning) of 
emphysema-like changes and inflammation predict 
long-term outcome (ie, recurrence of pneumothorax 
within 12 months)?
 ► Can digitally measured air leak and its evolution 
over treatment predict short-term clinical trajectory 
in patients with pneumothorax, including failure of 
treatment (ie, prolonged air leak or non-expanded 
lung)?
study dEsIgn
Two hundred and thirty-six patients with PSP requiring 
an intervention will be recruited from UK centres (see 
online supplementary appendix A for the list of UK 
centres). Patients will be randomised 1:1 to either inser-
tion of an ambulatory device (Rocket Pleural Vent) 
or to standard care (aspiration ± standard chest drain 
insertion) as per the British Thoracic Society (BTS) 
guidelines.7 Patients who do not require an interven-
tion will be invited to participate in an observational 
cohort study, with the results of this cohort published 
separately.
PAtIEnt InvolvEMEnt
Patients were involved in the design and conduct of 
this research. During the feasibility stage, priority of 
the research question, choice of outcome measures and 
methods of recruitment were informed by discussions 
with patients while in hospital and at follow-up in clinic. 
A patient representative is an independent member of 
the trial steering committee.
PArtIcIPAnt sElEctIon
All patients presenting with spontaneous pneumo-
thorax to emergency departments or acute medical 
teams will be assessed for eligibility. Patients may only 
be randomised once into the RAMPP trial. However, if 
a patient initially enrolled in the observational cohort 
subsequently requires treatment, they can be re-enrolled 
(and reconsented) for randomisation into the interven-
tional component of the trial.
Inclusion criteria
 ► Presenting with spontaneous pneumothorax as 
confirmed by a chest radiograph (CXR) or a CT scan.
 ► Age between 16 and 55 years old.
 ► Ability to consent to participation.
Exclusion criteria
 ► Known or suspected underlying lung disease 
(including >20 pack-year smoking history).
 ► Evidence of tension pneumothorax (defined as 
clinical or radiographic evidence of significantly 
increased intrapleural pressure causing haemody-
namic compromise requiring urgent decompres-
sion). These patients should be treated immediately 
as medical emergencies.
 ► Women who are pregnant or lactating.
 ► Inability to consent or comply with the trial 
requirements.
 ► Contraindication to thoracic procedure (only applies 
to patients being enrolled into the intervention or 
control arms, ie, not observational cohort).
 ► Any other significant disease or disorder which, in the 
opinion of the investigator, may either put the partic-
ipants at risk because of participation in the trial, or 
may influence the result of the trial, or the partici-
pant’s ability to participate in the trial.
‘Mild’ asthma is not considered an exclusion crite-
rion. Patients with a diagnosis of asthma in childhood/
young adulthood who do not require the use of a regular 
‘preventer’ inhaler (ie, inhaler containing a steroid or 
long-acting beta-agonist) and have never been hospital-
ised due to asthma remain eligible for participation in 
this study.
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Patients requiring intervention can be enrolled and 
randomised up to 24 hours after presentation, as long 
as they are still an inpatient, have an ongoing symp-
tomatic pneumothorax despite initial intervention (eg, 
patients initially treated with aspiration overnight) and 
now require chest drain insertion. Patients not requiring 
intervention can be enrolled into the observational 
cohort up to 2 weeks after their initial presentation.
InforMEd consEnt
Once an eligible patient is identified and agrees to 
participate in the study, informed written consent will 
be obtained by the principal investigator or other suit-
ably qualified delegated personnel. As pneumothorax is 
an acute medical problem, it would not be appropriate 
to wait the usual 24 hours to allow patients time to read 
the patient information leaflets, prior to intervention. 
However, ideally the patient should still be given a reason-
able short period of time to read, digest and ask ques-
tions about the study, prior to an approach for consent.
rAndoMIsAtIon And blIndIng
Patients will be randomised using a centralised, 
web-based randomisation system with each patient being 
assigned a unique trial number. Minimisation with a 
residual random component will occur, for the minimisa-
tion factors of (1) recruiting centre and (2) size of pneu-
mothorax (≥4 cm vs <4 cm) at presentation.
Due to the nature of the interventions, patients and 
clinicians cannot be blinded to allocation, and therefore 
code-breaking is not required for this trial. However, 
the objective ‘fitness for discharge’ data will be blind-re-
viewed after the trial by an independent assessor blind 
to treatment arm (ie, objective blind outcome assess-
ment) and compared with actual time spent in hospital at 
study end. Recurrence rates at 12 months will be blindly 
assessed by an independent assessor by reviewing patient 
CXRs and hospital records for readmissions at study end. 
In addition, the clinician responsible for making a deci-
sion to discharge a patient will be blinded to the air leak 
measurements recorded as part of the trial protocol.
IntErvEntIons
Once the patient has been identified as having a PSP 
by CXR, the decision to intervene will be made on the 
basis of the current BTS guidelines: large (interpleural 
distance at the level of hilum ≥2 cm) and/or sympto-
matic patients will be randomised to the following:
Intervention arm: ambulatory device (rocket Pleural vent)
An ambulatory device (Pleural Vent, Rocket Medical) 
should be inserted immediately after randomisation, 
using local anaesthetic. Researchers and local clinicians 
will be trained in inserting the device. The patient is then 
observed for 1–2 hours to check for clinical stability, after 
which a repeat CXR is performed (see figure 1).
If CXR shows insufficient re-expansion of the lung†, 
the pleural vent should remain in place and the patient 
can be discharged with device in situ if the patient fulfils 
the ‘Fitness for discharge’ criteria, which are all of the 
following:
 ► Patient agreement.
 ► Clinically stable cardiorespiratory observations 
(oxygen saturation, respiratory and heart rate, blood 
pressure).
 ► No increase in size of pneumothorax (since last 
review).
 ► Not requiring oxygen or other ventilator assistance.
 ► Patient is mobile and independent to self-care.
 ► Written information on point of contact if there are 
concerns and follow-up plan.
 ► Patient lives with a responsible person at home and is 
able to help the patient if required.
Any patient not meeting these criteria should remain 
as an inpatient and be reviewed daily.
If discharged, patients should be seen every 1–2 days 
until day 4; ideally daily, but once over the weekend is 
sufficient if clinically stable. At each review, if there is 
sufficient re-expansion of the lung† and no ongoing air 
leak clinically††, the responsible clinician can consider 
removing the device and the patient can be discharged 
home. As standard practice, a postremoval CXR should be 
performed to ensure that the lung has not recollapsed. If 
the CXR shows that the pneumothorax has recurred, the 
patient should be admitted to the respiratory ward with 
consideration of placement of a standard chest drain.
*‘Sufficient re-expansion’ is defined as complete or 
almost complete re-expansion (only a very small [<1 cm] 
rim of air apically) on CXR.
**Ongoing air leak assessed by attempted aspiration 
through the device using a syringe and connector: if the 
device is patent (as assessed by movement of the inbuilt 
diaphragm) but unable to aspirate (ie, draw air back 
through syringe), then there is no ongoing air leak; if 
able to aspirate air freely, then there is ongoing leak and 
active pneumothorax.
control arm: standard management as per the bts guidelines
Treatment in this arm is as per the BTS Pleural Guide-
lines 2010.7 In brief, needle aspiration (NA) should be 
attempted under local anaesthetic using 14–16 gauge 
cannula and syringe, aspirating a maximum of 2.5 L. The 
patient should be observed for 1–2 hours to check for 
clinical stability and a repeat CXR should be performed. 
If the repeat CXR after shows sufficient re-expansion of 
the lung, the patient can be discharged home. However, 
if the lung has not sufficiently re-expanded, then a small-
bore chest drain (≤14F) should be inserted and attached 
to an underwater seal, and the patient admitted to 
hospital.
Although initial aspiration is recommended, the 
responsible clinician may decide to proceed directly to 
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Figure 1 Study flow chart. CXR, chest radiograph; RAMPP, Randomised Ambulatory Management of Primary 
Pneumothorax.
chest drain insertion and admission at their discretion 
(and according to the BTS guidelines).
Decisions regarding drain removal are as per the stan-
dard practice at the participating centre, but typically will 
include the following: no further air leak as demonstrated 
by a non-bubbling chest drain and full lung expansion on 
CXR. As standard practice, a postremoval CXR should 
be performed to ensure that the lung has not collapsed. 
‘Fitness for Discharge’ criteria for discharge will be 
conducted daily to provide equality between treatment 
arms (criteria as above).
study AssEssMEnts
This study will use a web-based, dedicated and validated 
clinical trial database designed for remote electronic 
data capture (OpenClinica). All baseline demographic 
data, daily clinical observations, adverse events (AEs) 
and healthcare usage data will be uploaded directly onto 
OpenClinica. The full schedule of study procedures is 
found in online supplementary appendix B.
All patients will document a visual analogue scale 
(VAS) score for thoracic pain and breathlessness at base-
line (day 0, prior to procedure and postprocedure) and 
daily for the next 4 days of assessment. Quality of life 
questionnaires (EQ-5D-5L) will be collected at baseline. 
VAS and EQ-5D-5L questionnaires will be conducted on 
completion of treatment and at each follow-up point (see 
below).
blood samples and storage
If taken as part of routine clinical care, the patient’s base-
line blood tests (haemoglobin, white cell count, platelet 
count, electrolytes, liver function tests and clotting tests) 
will be recorded. Patients will be consented to have an 
additional blood test for highly sensitive C reactive 
protein, which will be sent to the ORTU for analysis. This 
 o
n
 13 M
ay 2019 by guest. Protected by copyright.
http://bmjopenrespres.bmj.com/
BM
J O
pen Resp Res: first published as 10.1136/bmjresp-2019-000403 on 11 April 2019. Downloaded from 
Hallifax R, et al. BMJ Open Resp Res 2019;6:e000403. doi:10.1136/bmjresp-2019-000403 5
Open access
blood will be centrifuged, labelled and stored as part of 
the ORTU Collection of the Oxford Radcliffe Biobank. 
Genetic compositional analysis may also be undertaken 
on participants’ samples if specific consent for this has 
been obtained.
digital air leak measurement
All patients requiring pleural intervention will have digital 
measurement of air leak using a digital measuring device 
(Thopaz+, Medela, Switzerland). Measurements will be 
taken immediately postintervention (day 0) for the ambu-
latory device or chest drain, then daily at around the same 
time on days 1–4 (or until chest drain/device removal). 
On each occasion the Thopaz+ (Medela) device should 
be attached to the chest drainage device (either ambu-
latory device or standard chest drain, dependent on the 
arm of the trial) for 10 min, with the device set to −0.4 
kPa (ie, providing no suction but as close to normal phys-
iological pleural pressure as possible). During this time, 
the air leak measurement should be recorded by reading 
the measurement at 1, 5 and 10 min. These data will be 
uploaded to OpenClinica.
failure of medical treatment
There is no robust evidence on the ideal timing for 
surgical intervention. Current BTS guidelines suggest 
that cases of persistent air leak or non-re-expansion 
should be referred after 3–5 days.7 To achieve objective 
outcomes for this study, the following measurable and 
documentable criteria have been developed to ensure 
consistent practice and will be recorded as part of the 
study in all cases. Referral for thoracic surgery will occur 
in the presence of all of the following:
 ► Day 4 postinsertion of chest drain, persistent air 
leak as measured by ‘bubbling’ chest drain attached 
to underwater seal, or evidence of ongoing air leak 
through an ambulatory device.
 ► Persistent pneumothorax on CXR.
 ► Patient agreement.
 ► No contraindication to thoracic surgery.
In all cases, the clinical parameters and radiology (both 
those referred to surgery and those successfully treated 
with medical management) will be blindly assessed at 
the end of the study to ensure the discharge and surgery 
criteria were robustly followed.
ct scan
CT scan will be conducted in all patients (approximately 
2–4 weeks after enrolment) to detect lung parenchymal 
abnormalities. These should be conducted as per protocol 
(see online supplementary appendix C), including 
high-resolution limited cuts apically. Any patient who has 
a CT as part of their clinical care will not be required to 
have an additional scan. The CT regimen was designed 
to be low dose (total 3.4 mSv, equivalent of 1-year back-
ground radiation). The benefit of CT scanning in every 
young patient with pneumothorax is not proven and 
controversial due to the additional radiation dose. This 
trial aims to determine whether CT findings can predict 
long-term outcomes and therefore be of clinical utility.
trIAl follow-uP
All patients will be followed up 1 week after completion 
of treatment, then at 1, 6 and 12 months from enrolment. 
At each time point, the patient will complete the VAS and 
EQ-5D-5L questionnaires, have a CXR, and documenta-
tion of smoking status and any recurrence of pneumo-
thorax. Every effort should be made to ensure patients 
attend their follow-up appointments. However, patients 
not able to attend may be contacted by phone to check 
for complications or recurrence. If this is not possible, 
then data on recurrence can be collected through 
medical notes.
PrIMAry outcoME
The primary outcome measure will be total length of 
stay in hospital to include primary hospital stay and 
readmissions up to 30 days postrandomisation. Patients 
remaining in hospital overnight will be classed as 1 day; 
those discharged on the same day (after either successful 
NA (needle aspiration) treatment or treatment with 
pleural vent) will have a zero length of stay. These attend-
ances will be captured in the health economic analyses. 
Thirty days has been chosen on the basis of previous data 
suggesting that the majority of conservatively treated 
(non-surgical) air leaks will have resolved within 14 
days of initial treatment in pneumothorax, and a 30-day 
outcome point is therefore conservative and will reliably 
capture all related readmissions. Readmission will be 
defined as the requirement of emergency (non-planned) 
visit to hospital requiring any form of contact with medical 
services (not restricted to further pleural interventions) 
in relation to the pneumothorax. This will not include 
planned day case reviews for the outpatient treated popu-
lation.
sEcondAry outcoMEs
The following are the secondary research questions:
 ► Is ambulatory care and early discharge safe and 
cost-effective?
 ► Is patient experience improved with an ambulatory 
device, including pain of procedure, breathlessness, 
quality of life assessments (EQ-5D-5L) and time to 
return to working status?
 ► What is the recurrence rate of pneumothorax over 6 
and 12 months?
 ► Does radiological evidence (on CT scanning) of 
emphysema-like changes and inflammation predict 
long-term outcome (ie, recurrence of pneumothorax 
within 12 months)?
 ► Can digitally measured air leak and its evolution 
over treatment predict short-term clinical trajectory 
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in patients with pneumothorax, including failure of 
treatment (ie, prolonged air leak or non-expanded 
lung)?
sAMPlE sIzE cAlculAtIon
The sample size for the primary outcome was determined 
to detect a difference in hospital stay of 2.3 days: from 
a mean of 4 days admission in the control arm to an 
expected mean of 1.7 days in the intervention arm (SD 
in both groups 6.0). These means include the calculation 
that up to 50% of the control arm may be successfully 
treated with aspiration alone (ie, zero-day admission). It 
is assumed, conservatively, that ~20% of patients in the 
intervention arm will require a readmission. Therefore, 
to detect this difference, accounting for non-parametric 
data requires 236 patients in total, including a 10% attri-
tion rate, an 80% power and a 5% two-sided significance 
level. Our previous pleural studies have demonstrated an 
attrition rate for the primary outcome measure of <5%.
End of trIAl
The trial will end once 236 patients have been randomised 
and all patients have completed 12 months of trial 
follow-up.
stAtIstIcAl AnAlysIs PlAn
The primary outcome will be analysed using the Mann-
Whitney U test. The median hospital stay (expected to 
be non-normally distributed) will be reported for each 
arm, and the 95% CI for difference in medians will be 
calculated using an exact test.
As a sensitivity analysis, survival analysis techniques will 
be used. Kaplan-Meier survival curves will be presented 
graphically. Survival (ie, time without recurrence of pneu-
mothorax and in follow-up) will be compared between 
arms using the Gehan-Breslow-Wilcoxon test, which is 
more appropriate than the log-rank test when the rate of 
early events is high. Cox proportional hazards regression 
will also be used to calculate the HR and 95% CI.
Continuous secondary outcome measures will be 
analysed using analysis of covariance adjusting for base-
line score. Results will be reported as adjusted mean 
difference between treatment arms, with 95% CI and 
p values. Categorical secondary outcome measures will 
be analysed using the χ2 test. Time to event secondary 
outcome measures will be analysed in the same way as the 
time to event analysis of the primary outcome measure. 
Patient-related factors and time to return to work will be 
collated blindly and verified by a central panel, unaware 
of interventional arm and/or requirement of surgery.
A Consolidated Standards of Reporting Trials diagram 
will be presented, including the number of patients 
screened for the study, the numbers randomised, the 
numbers receiving the interventions, the numbers lost to 
follow-up and excluded (with reasons), and the number 
of patients included in the primary analysis.
sAfEty rEPortIng
Data will be collected at each patient’s trial visit regarding 
any serious adverse events (SAE; as defined by good clin-
ical practice guidelines). All SAEs causally related to trial 
interventions will be reported to the sponsor and to the 
relevant oversight bodies, and will be followed until they 
resolve or stabilise.
SAEs in this study which should be reported immedi-
ately (ie, within 24 hours) to ORTU include tension pneu-
mothorax occurring during treatment (until discharge), 
blockage of drain with clinical consequences (eg, patient 
unwell, further procedure), major haemorrhage which 
requires specific intervention (eg, blood transfusion) and 
any additional emergency pleural procedure as deemed 
necessary by the responsible local physician (eg, large-
bore chest drain insertion).
The following are considered to be expected AEs asso-
ciated with the proposed trial interventions for this trial:
 ► Pain at drain site.
 ► Minor haemorrhage not requiring specific interven-
tion such as blood transfusion or surgery.
 ► Subcutaneous emphysema.
 ► Pleural infection.
 ► Unintentional removal (‘falling out’).
 ► Recurrence of pneumothorax/worsening of 
ongoing pneumothorax (if no evidence of initial full 
resolution).
 ► Re-expansion pulmonary oedema.
 ► Any further (non-emergency) pleural procedure 
required.
Recurrence of pneumothorax is expected in approx-
imately 33% of PSP within 1 year. This is defined as a 
recurrence of pneumothorax (if fully resolved and 
documented as fully resolved) or worsening of ongoing 
pneumothorax (if discharged but no evidence of full 
resolution). These do not need to be reported as an SAE 
(even if they meet the criteria of requiring hospitalisation 
or prolongation of their hospital stay), as all the informa-
tion will be explicitly captured at the follow-up visit.
cost-EffEctIvEnEss AnAlysIs
The perspective adopted in the economic analysis will 
be that of the UK National Health Service. As a result 
data will be collected on hospital stay, outpatient contact 
(primary and secondary care) and resource usage.
As the main outcome measure in the economic eval-
uation will be incremental cost per quality-adjusted life 
year (QALY) gained, generic quality of life informa-
tion will be collected. The EuroQol EQ-5D-5 levels—a 
widely used generic multiattribute utility scale—will be 
completed for each patient at baseline and at 1-week, 
1-month and 6-month assessments to measure patients’ 
general health-related quality of life. For QALY construc-
tion, EQ-5D-5L results will be translated into utility values 
using published UK population valuations.
A within-trial cost-utility analysis will explore the incre-
mental cost per QALY gained of ambulatory care when 
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compared with standard care. Cost and effect results will 
be reported as means with SD, with mean differences 
between the two patient groups reported alongside 95% 
CIs. Cost-effectiveness and health economic analyses may 
be published in a separate publication to the primary 
trial results.
sAfEty MonItorIng And IntErIM AnAlysEs
The Data Safety Monitoring Committee (DSMC) consists 
of independent experts (medical experts and a statisti-
cian) external to a trial who assess the progress, conduct, 
participant safety and critical endpoints of a clinical 
trial. A blinded interim analysis of the primary outcome 
(hospital stay) will be undertaken after approximately 
50% of patients have been recruited in order to assess the 
assumptions made in the sample size calculation, and not 
to directly compare the intervention arms. No correction 
of the significance level of the final analysis is planned on 
this single assessment of early event rate by the DSMC.
chAngEs to thE Protocol AftEr trIAl coMMEncEMEnt
The trial details documented here are consistent with the 
RAMPP trial protocol V.8.0 (date: 3 November 2017). A 
summary of the trial amendments can be found in online 
supplementary appendix D. Major amendments included 
reducing the inclusion age to ≥16 years old, clarification 
that patients enrolled in the observational cohort study 
could subsequently be enrolled in the treatment part of 
the study if they require intervention, and clarification of 
pneumothorax recurrence and re-expansion pulmonary 
oedema as expected AEs.
PublIcAtIon PolIcy
The trial results will be presented at regional, national 
and international conferences and scientific meetings 
with publication in a peer-reviewed journal (author-
ship will be according to the journal’s guidelines). A 
lay summary of the study results will be circulated to 
consented patients and relevant funding bodies.
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